marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 11-07-2024
Homology Medicines Balance Sheet 2011-2024 | FIXX
Annual Balance Sheet Homology Medicines
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-4.51 M | -84.4 M | -202 M | -53.8 M | -38.2 M | -51.6 M | -11.4 M | - | - | - | - | - |
Long Term Debt |
27.9 M | 23.7 M | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
1.56 M | 246 K | 2.5 M | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | 45.1 M | 39.7 M | 38.9 M | 30.4 M | 17.7 M | - | - | - | - | - |
Total Current Liabilities |
22.6 M | 17.2 M | 22.7 M | 12.4 M | 25.4 M | - | - | - | - | - | - | - |
Total Liabilities |
50.5 M | 42.1 M | 67.7 M | 52.1 M | 64.4 M | 39.2 M | 24.1 M | - | - | - | - | - |
Deferred Revenue |
1.16 M | 3.21 M | 5.63 M | 809 K | 3.68 M | 3.34 M | - | - | - | - | - | - |
Retained Earnings |
-429 M | -424 M | -328 M | -200 M | -97.4 M | -40.2 M | -10.2 M | - | - | - | - | - |
Total Assets |
228 M | 212 M | 264 M | 311 M | 259 M | 138 M | 14.2 M | - | - | - | - | - |
Cash and Cash Equivalents |
34 M | 108 M | 217 M | 53.8 M | 38.2 M | - | - | - | - | - | - | - |
Book Value |
178 M | 170 M | 196 M | 259 M | 195 M | 98.3 M | -9.89 M | - | - | - | - | - |
Total Shareholders Equity |
178 M | 170 M | 196 M | 259 M | 196 M | -39.5 M | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Homology Medicines
| 2024-Q3 | 2024-Q2 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | 38.6 M | 26.6 M | 27 M | 27.5 M | 27.9 M | 28.3 M | 23.6 M | 23.5 M | 23.7 M | 11.6 M | 12 M | 12.5 M | 12.9 M | 12.9 M | 12.9 M | 12.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
86.2 M | 90.7 M | 119 M | 51.9 M | 50 M | 46 M | 50.5 M | 53.6 M | 44.3 M | 44.7 M | 42.1 M | 32.2 M | 34.3 M | 33.9 M | 67.7 M | 67.7 M | 67.7 M | 67.7 M | 52.1 M | 52.1 M | 52.1 M | 52.1 M | 62.7 M | 62.7 M | 62.7 M | 62.7 M | 39.2 M | 39.2 M | 39.2 M | 39.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | 354 K | 1.16 M | 1.96 M | 2.76 M | 3.21 M | 3.21 M | 3.21 M | 4.01 M | 5.18 M | 5.63 M | 5.63 M | 5.63 M | 5.63 M | 809 K | 809 K | 809 K | 809 K | 3.68 M | 3.61 M | 3.5 M | 3.41 M | 3.34 M | 3.34 M | 3.34 M | 3.34 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-221 M | -203 M | -187 M | -526 M | -493 M | -458 M | -429 M | -395 M | -361 M | -332 M | -424 M | -391 M | -360 M | -329 M | -328 M | -328 M | -328 M | -328 M | -200 M | -200 M | -200 M | -200 M | -95.8 M | -95.8 M | -95.8 M | -95.8 M | -40.2 M | -40.2 M | -40.2 M | -40.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
105 M | 124 M | 47.1 M | 140 M | 169 M | 198 M | 228 M | 263 M | 285 M | 311 M | 212 M | 231 M | 259 M | 235 M | 264 M | 264 M | 264 M | 264 M | 311 M | 311 M | 311 M | 311 M | 259 M | 259 M | 259 M | 259 M | 138 M | 138 M | 138 M | 138 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
89.1 M | 97.7 M | 25.6 M | 36.3 M | 20.1 M | 39.5 M | 34 M | 43.2 M | 176 M | 248 M | 108 M | 95.8 M | 116 M | 104 M | 217 M | 217 M | 217 M | 217 M | 53.8 M | 53.8 M | 53.8 M | 53.8 M | 38.2 M | 38.2 M | 38.2 M | 38.2 M | 51.6 M | 51.6 M | 51.6 M | 51.6 M | 11.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
18.3 M | 33.5 M | -71.5 M | 88.2 M | 119 M | 152 M | 178 M | 209 M | 240 M | 266 M | 170 M | 199 M | 225 M | 201 M | 196 M | 196 M | 196 M | 196 M | 259 M | 259 M | 259 M | 259 M | 196 M | 196 M | 196 M | 196 M | 98.3 M | 98.3 M | 98.3 M | 98.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
18.3 M | 33.5 M | -183 M | -156 M | -143 M | 152 M | 178 M | 209 M | 240 M | 266 M | 170 M | 199 M | 225 M | 201 M | 196 M | 196 M | 196 M | 196 M | 259 M | 259 M | 259 M | 259 M | 196 M | 196 M | 196 M | 196 M | -39.5 M | -39.5 M | -39.5 M | -39.5 M | -9.89 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency